Filing Flows › TG Therapeutics (TGTX) › Q2 2026 › vs Q2 2025
TG Therapeutics (TGTX) Q2 2026 vs Q2 2025 (year over year)
TG Therapeutics's revenue rose $99.2M (+70%) from $141M in Q2 2025 to $240M in Q2 2026. The biggest changes: Product +$97.0M (+70%); License +$2.2M (+97%). Operating margin 9.0% against 24.7% (-15.7 pts).
TG Therapeutics, Q2 2026: revenue $240M (+70% year over year), operating margin 9.0%, net earnings $7.8M, operating cash flow $39.3M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Operating margin | 9.0% | 24.7% | -15.7 pts |
| Net margin | 3.2% | 20.0% | -16.7 pts |
| Free cash flow margin | 16.2% | 5.2% | +11.0 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Product | $236M | $139M | $97.0M | +70% |
| License | $4.5M | $2.3M | $2.2M | +97% |
| Revenue | $240M | $141M | $99.2M | +70% |
| Operating profit | $21.7M | $34.8M | −$13.2M | -38% |
| Costs & expenses | $219M | $106M | $112M | +106% |
| Pre-tax earnings | $10.2M | $30.9M | −$20.7M | -67% |
| Other expense, net | $11.4M | $3.9M | $7.5M | +192% |
| Cost of revenue | $41.2M | $18.9M | $22.3M | +118% |
| Research & development | $95.3M | $31.8M | $63.6M | +200% |
| SG&A | $82.1M | $55.6M | $26.5M | +48% |
| Net earnings | $7.8M | $28.2M | −$20.4M | -72% |
| Income tax | $2.5M | $2.7M | −$280K | -10% |
| Depreciation & amortization | $53K | $13K | $40K | +308% |
| Share-based compensation | $27.9M | $16.4M | $11.5M | +70% |
| Working capital & other | $3.6M | −$37.1M | $40.7M | — |
| Operating cash flow | $39.3M | $7.4M | $31.8M | +428% |
| Free cash flow (OCF − capex) | $39.0M | $7.4M | $31.6M | +427% |
| Capital expenditures | $293K | $42K | $251K | +598% |
Questions
How much did TG Therapeutics's revenue grow year over year in Q2 2026?
TG Therapeutics's revenue rose $99.2M (+70%) from $141M in Q2 2025 to $240M in Q2 2026.
What drove TG Therapeutics's revenue change in Q2 2026?
Product +$97.0M (+70%); License +$2.2M (+97%).